Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE versus SODIUM NITROPRUSSIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE versus SODIUM NITROPRUSSIDE.
Hydralazine vs SODIUM NITROPRUSSIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased peripheral vascular resistance and blood pressure. Its exact mechanism is unclear but may involve interference with calcium movement and increased cGMP levels.
Sodium nitroprusside is a prodrug that releases nitric oxide (NO) in vascular smooth muscle cells, activating guanylate cyclase and increasing cGMP, leading to vasodilation of both arterial and venous vessels.
10-50 mg orally every 6 hours, titrate to maximum 300 mg/day; 10-20 mg intramuscularly or intravenously every 4-6 hours as needed.
Intravenous infusion: Initial 0.3-0.5 mcg/kg/min; titrate up to 10 mcg/kg/min, maximum 10 mcg/kg/min for up to 10 minutes. Usual therapeutic dose: 3 mcg/kg/min. Max cumulative dose: 3.5 mg/kg.
None Documented
None Documented
Clinical Note
moderateHydralazine + Benzydamine
"Hydralazine may decrease the antihypertensive activities of Benzydamine."
Clinical Note
moderateHydralazine + Droxicam
"Hydralazine may decrease the antihypertensive activities of Droxicam."
Clinical Note
moderateHydralazine + Loxoprofen
"Hydralazine may decrease the antihypertensive activities of Loxoprofen."
Clinical Note
moderateHydralazine + Clonixin
"Hydralazine may decrease the antihypertensive activities of Clonixin."
The terminal elimination half-life of hydralazine is approximately 2-4 hours in patients with normal renal function. However, the duration of antihypertensive effect may be longer (6-12 hours) due to tissue binding and slow release from vascular smooth muscle. In renal impairment, half-life may extend to 7-16 hours, necessitating dose adjustment.
Sodium nitroprusside itself has a half-life of approximately 2 minutes (converted to cyanide in erythrocytes); the metabolite thiocyanate has a terminal half-life of 2.7-7 days (prolonged in renal impairment, requiring monitoring)
Hydralazine is primarily metabolized in the liver via N-acetylation and hydroxylation. Approximately 80-90% of the drug is eliminated in urine as metabolites, with less than 10% excreted unchanged. A small fraction appears in feces via biliary excretion.
Renal: approximately 75% as thiocyanate (metabolite) with 25% unchanged; biliary/fecal: minimal (<5%)
Category A/B
Category C
Vasodilator
Vasodilator